AbbVie Targets Vitiligo Approval to Drive Rinvoq Growth

The North Chicago-based biopharmaceutical giant filed submissions with the U.S. Food and Drug Administration and the European Medicines Agency on Tuesday. The applications specifically target non-segmental vitiligo, a condition where the immune system attacks pigment-producing cells, resulting in symmetrical white patches across the body. While topical treatments exist, the company aims to position Rinvoq as a more comprehensive oral option for both adults and adolescents.

A Strategic Pillar for Revenue

The expansion into vitiligo is a critical component of AbbVie’s long-term growth strategy as it seeks to diversify its portfolio. Rinvoq is already authorized for several conditions, including rheumatoid arthritis and eczema. According to company projections, Rinvoq is expected to generate more than $11 billion in annual revenue by 2027.

Vitiligo remains the most common depigmenting disorder globally, yet treatment options have historically been limited to localized therapies. AbbVie’s move to secure a "first-in-class" systemic designation underscores the competitive race in the immunology sector. The company claims that a green light for this indication would provide a vital new tool for managing the systemic nature of the disease rather than just treating individual patches.